Measles on the Brink: The Unsettling Rise of Treatments as Vaccination Rates Plummet The resurgence of measles cases in the US has been met with alarm, and a disturbing trend is emerging: the development of treatments for a disease that was once all but eradicated.
As vaccination rates continue to decline, biotech companies and researchers are racing to develop monoclonal antibodies and antivirals to combat the virus.
Measles is no longer just a disease of the unvaccinated; it's now a growing concern for immunocompromised individuals, infants under 12 months old, and communities with low vaccination rates.